60 Degrees Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Geoffrey Dow

Chief executive officer

US$125.6k

Total compensation

CEO salary percentage	100.0%
CEO tenure	2.4yrs
CEO ownership	3.4%
Management average tenure	1.6yrs
Board average tenure	1.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Geoffrey Dow's remuneration changed compared to 60 Degrees Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$8m
Jun 30 2024	n/a	n/a	-US$2m
Mar 31 2024	n/a	n/a	-US$853k
Dec 31 2023	US$126k	US$126k	-US$4m
Sep 30 2023	n/a	n/a	-US$4m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$55k	US$55k	-US$6m
Sep 30 2022	n/a	n/a	-US$6m
Dec 31 2021	US$520k	US$520k	-US$4m
Dec 31 2020	US$283k	US$283k	-US$3m

Compensation vs Market: Geoffrey's total compensation ($USD125.56K) is below average for companies of similar size in the US market ($USD652.28K).

Compensation vs Earnings: Geoffrey's compensation has increased whilst the company is unprofitable.

CEO

Geoffrey Dow (50 yo)

2.4yrs

Tenure

US$125,555

Compensation

Dr. Geoffrey Stuart Dow serves as President, Chief Executive Officer and Director at 60 Degrees Pharmaceuticals, Inc. since June 1, 2022. Dr. Dow is Chairman, President and CEO of 60° Pharmaceuticals, LLC....

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Geoffrey Dow	Chairman	no data	US$125.56k	3.41% $ 55.5k
Tyrone Miller	CFO & Treasurer	1.8yrs	US$135.63k	0.79% $ 12.9k
Bryan Smith	Chief Medical Officer	8.8yrs	no data	no data
Kristen Landon	Chief Commercial Officer	less than a year	no data	no data
Jennifer Herz	Director	1.3yrs	no data	no data

1.6yrs

Average Tenure

53.5yo

Average Age

Experienced Management: SXTP's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Geoffrey Dow	Chairman	2.4yrs	US$125.56k	3.41% $ 55.5k
Charles Allen	Independent Director	1.3yrs	US$121.83k	0.063% $ 1.0k
Stephen Toovey	Independent Director	1.3yrs	US$120.33k	0.063% $ 1.0k
Paul Field	Independent Director	1.3yrs	US$120.33k	0.063% $ 1.0k
Cheryl Xu	Director	1.3yrs	US$117.83k	2.21% $ 35.9k

1.3yrs

Average Tenure

56yo

Average Age

Experienced Board: SXTP's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

60 Degrees Pharmaceuticals Management

Management criteria checks 1/4

Key information

Recent management updates

60 Degrees Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

60 Degrees Pharmaceuticals Inc. Announces ARAKODA Promotional Pilot in Advance of Expanded U.S. Launch

60 Degrees Pharmaceuticals, Inc. announced that it expects to receive $4 million in funding

60 Degrees Pharmaceuticals, Inc. announced that it expects to receive $4 million in funding

60 Degrees Pharmaceuticals, Inc. announced that it expects to receive $4 million in funding

60 Degrees Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$4.68 loss

60 Degrees Pharmaceuticals, Inc. Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

60 Degrees Pharmaceuticals Announces 1:12 Reverse Stock Split to Bring the Company into Compliance with the Nasdaq's $1.00 Minimum Bid Price Requirement for Maintaining its Nasdaq Listing

New major risk - Share price stability

60 Degrees Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.253603 million.

60 Degrees Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.253603 million.

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia Microti Despite Prior Treatment

60 Degrees Pharmaceuticals, Inc. Announces First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center

60 Degrees Pharmaceuticals, Inc. Enters into an Agreement with Tufts Medical Center in Boston to Conduct the First Clinical Trial of Tafenoquine in Treating Human Babesiosis Patients

Consensus revenue estimates fall by 13%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

60 Degrees Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2024

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

60 Degrees Pharmaceuticals Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

High number of new and inexperienced directors

60 Degrees Pharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $2.4001 million.

60 Degrees Pharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $2.400101 million.

60 Degrees Pharmaceuticals, Inc. Plans Pivotal Babesiosis Study with Tafenoquine

60 Degrees Pharmaceuticals, Inc. Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease

60 Degrees Pharmaceuticals, Inc. announced delayed 10-Q filing

60 Degrees Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Required for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

60 Degrees Pharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Required for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

60 Degrees Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases

60 Degrees Pharmaceuticals, Inc.'s Subsidiary 60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

Second quarter 2023 earnings released

60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria

60 Degrees Pharmaceuticals, Inc. Registers ACLR8-LR

New major risk - Market cap size

High number of new and inexperienced directors

60 Degrees Pharmaceuticals Receives Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects

60 Degrees Pharmaceuticals, Inc. has completed an IPO in the amount of $7.500004 million.

60 Degrees Pharmaceuticals, Inc. has completed an IPO in the amount of $7.500004 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age